Lantern Pharma Inc. SEC filings LTRN
Lantern Pharma Inc. has 262 filings in SEC EDGAR's recent list, going back to Jan 14, 2019. Its latest annual report, Form ARS, was filed on Oct 21, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 14, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 1, 2026 (listing notice). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| ARS | Annual report to shareholders | Oct 21, 2026 | Dec 31, 2025 |
| DEF 14A | Proxy statement | Oct 19, 2026 | Oct 19, 2026 |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Oct 13, 2026 | — |
| PRE 14A | Preliminary proxy statement | Oct 8, 2026 | Oct 8, 2026 |
| 8-K |
Current report
Listing notice
|
Oct 1, 2026 | Sep 25, 2026 |
| 8-K |
Current report
Material agreement, Unregistered share sale
|
Sep 30, 2026 | Sep 28, 2026 |
| 424B5 | Prospectus supplement | Sep 30, 2026 | — |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 24, 2026 | Sep 23, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 23, 2026 | Sep 23, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Aug 14, 2026 | Aug 14, 2026 |
| 10-Q | Quarterly report | Aug 14, 2026 | Jun 30, 2026 |
| SCHEDULE 13G | Ownership over 5% (passive) | Aug 4, 2026 | — |
| 8-K |
Current report
Regulation FD disclosure
|
Aug 3, 2026 | Aug 3, 2026 |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Jul 23, 2026 | — |
| EFFECT | Filing | Jun 18, 2026 | — |
| S-1 | Registration statement | Jun 12, 2026 | — |
| 8-K |
Current report
Regulation FD disclosure
|
Jun 2, 2026 | Jun 1, 2026 |
| D | Filing | May 21, 2026 | — |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | May 15, 2026 | — |
| 8-K |
Current report
Results of operations
|
May 15, 2026 | May 15, 2026 |
| 10-Q | Quarterly report | May 15, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Other events
|
May 14, 2026 | May 12, 2026 |
| 4 | Insider transaction | May 14, 2026 | May 12, 2026 |
| 4 | Insider transaction | May 14, 2026 | May 12, 2026 |
| 424B5 | Prospectus supplement | May 14, 2026 | — |
| 10-K/A | Amended annual report | Apr 30, 2026 | Dec 31, 2025 |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Apr 16, 2026 | — |
| 8-K |
Current report
Regulation FD disclosure
|
Apr 10, 2026 | Apr 9, 2026 |
| SCHEDULE 13G | Ownership over 5% (passive) | Apr 3, 2026 | — |
| 424B5 | Prospectus supplement | Mar 30, 2026 | — |
| 10-K | Annual report | Mar 30, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Mar 30, 2026 | Mar 30, 2026 |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Feb 23, 2026 | — |
| 8-K |
Current report
Regulation FD disclosure
|
Jan 23, 2026 | Jan 22, 2026 |
| 4 | Insider transaction | Jan 13, 2026 | Jan 9, 2026 |
| 4 | Insider transaction | Jan 13, 2026 | Jan 9, 2026 |
| 4 | Insider transaction | Jan 13, 2026 | Jan 9, 2026 |
| 4 | Insider transaction | Jan 13, 2026 | Jan 9, 2026 |
| 4 | Insider transaction | Jan 13, 2026 | Jan 9, 2026 |
| 4 | Insider transaction | Dec 22, 2025 | Dec 18, 2025 |
| 4 | Insider transaction | Dec 22, 2025 | Dec 18, 2025 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Nov 13, 2025 | Nov 13, 2025 |
| 10-Q | Quarterly report | Nov 12, 2025 | Sep 30, 2025 |
| 8-K |
Current report
Shareholder vote results
|
Sep 23, 2025 | Sep 19, 2025 |
| 4 | Insider transaction | Sep 23, 2025 | Sep 19, 2025 |
| 4 | Insider transaction | Sep 23, 2025 | Sep 19, 2025 |
| 4 | Insider transaction | Sep 23, 2025 | Sep 19, 2025 |
| 4 | Insider transaction | Sep 23, 2025 | Sep 19, 2025 |
| 4 | Insider transaction | Sep 23, 2025 | Sep 19, 2025 |
| 4 | Insider transaction | Sep 23, 2025 | Sep 19, 2025 |
| 4 | Insider transaction | Aug 20, 2025 | Aug 19, 2025 |
| 8-K |
Current report
Results of operations
|
Aug 13, 2025 | Aug 13, 2025 |
| 10-Q | Quarterly report | Aug 13, 2025 | Jun 30, 2025 |
| ARS | Annual report to shareholders | Aug 11, 2025 | Dec 31, 2024 |
| DEF 14A | Proxy statement | Aug 8, 2025 | Aug 8, 2025 |
| 3 | Initial insider ownership | Jul 30, 2025 | Jul 24, 2025 |
| 8-K |
Current report
Officer or director change, Bylaw or fiscal year change
|
Jul 29, 2025 | Jul 24, 2025 |
| PRE 14A | Preliminary proxy statement | Jul 28, 2025 | Jul 28, 2025 |
| 8-K |
Current report
Material agreement
|
Jul 3, 2025 | Jul 3, 2025 |
| 424B5 | Prospectus supplement | Jul 3, 2025 | — |
| 4 | Insider transaction | Jun 13, 2025 | Jun 13, 2025 |
| 4 | Insider transaction | Jun 13, 2025 | Jun 13, 2025 |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Jun 13, 2025 | — |
| 4 | Insider transaction | Jun 13, 2025 | Jun 10, 2025 |
| 4 | Insider transaction | Jun 13, 2025 | Jun 10, 2025 |
| 4 | Insider transaction | May 29, 2025 | May 27, 2025 |
| 4 | Insider transaction | May 29, 2025 | May 27, 2025 |
| 144 | Notice of proposed sale | May 27, 2025 | — |
| 144 | Notice of proposed sale | May 27, 2025 | — |
| 144 | Notice of proposed sale | May 27, 2025 | — |
| 144 | Notice of proposed sale | May 27, 2025 | — |
| 144 | Notice of proposed sale | May 27, 2025 | — |
| 10-Q | Quarterly report | May 15, 2025 | Mar 31, 2025 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
May 15, 2025 | May 15, 2025 |
| 10-K/A | Amended annual report | Apr 30, 2025 | Dec 31, 2024 |
| 10-K | Annual report | Mar 27, 2025 | Dec 31, 2024 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Mar 27, 2025 | Mar 27, 2025 |
| 8-K |
Current report
Officer or director change
|
Jan 10, 2025 | Jan 6, 2025 |
| 8-K |
Current report
Regulation FD disclosure
|
Nov 8, 2024 | Nov 7, 2024 |
| 10-Q | Quarterly report | Nov 7, 2024 | Sep 30, 2024 |
| 8-K |
Current report
Results of operations
|
Nov 7, 2024 | Nov 7, 2024 |
| 10-Q | Quarterly report | Aug 8, 2024 | Jun 30, 2024 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Aug 8, 2024 | Aug 8, 2024 |
| 4 | Insider transaction | Jul 26, 2024 | Jul 24, 2024 |
| 4 | Insider transaction | Jul 17, 2024 | Jul 15, 2024 |
| 4 | Insider transaction | Jul 17, 2024 | Jul 15, 2024 |
| 4 | Insider transaction | Jul 17, 2024 | Jul 15, 2024 |
| 4 | Insider transaction | Jul 17, 2024 | Jul 15, 2024 |
| 4 | Insider transaction | Jul 17, 2024 | Jul 15, 2024 |
| 4 | Insider transaction | Jul 17, 2024 | Jul 15, 2024 |
| 4 | Insider transaction | Jul 17, 2024 | Jul 15, 2024 |
| 8-K |
Current report
Shareholder vote results
|
Jun 17, 2024 | Jun 13, 2024 |
| EFFECT | Filing | Jun 10, 2024 | — |
| CORRESP | Letter to the SEC | Jun 6, 2024 | — |
| UPLOAD | Letter from the SEC | Jun 3, 2024 | — |
| 4 | Insider transaction | May 28, 2024 | May 23, 2024 |
| 4 | Insider transaction | May 28, 2024 | May 23, 2024 |
| 8-K |
Current report
Bylaw or fiscal year change
|
May 24, 2024 | May 23, 2024 |
| S-8 | Employee stock plan registration | May 24, 2024 | — |
| S-3 | Shelf registration | May 24, 2024 | — |
| 10-Q | Quarterly report | May 9, 2024 | Mar 31, 2024 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
May 9, 2024 | May 9, 2024 |
| ARS | Annual report to shareholders | May 3, 2024 | Dec 31, 2023 |
| DEF 14A | Proxy statement | Apr 29, 2024 | Apr 29, 2024 |
| 144 | Notice of proposed sale | Apr 26, 2024 | — |
| 144 | Notice of proposed sale | Apr 26, 2024 | — |
| 144 | Notice of proposed sale | Apr 26, 2024 | — |
| 144 | Notice of proposed sale | Apr 26, 2024 | — |
| 144 | Notice of proposed sale | Apr 26, 2024 | — |
| 10-K | Annual report | Mar 18, 2024 | Dec 31, 2023 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Mar 18, 2024 | Mar 18, 2024 |
| SC 13D/A | Amended ownership over 5% (active) | Mar 1, 2024 | — |
| 4 | Insider transaction | Feb 29, 2024 | Feb 27, 2024 |
| 4 | Insider transaction | Feb 29, 2024 | Feb 27, 2024 |
| 144 | Notice of proposed sale | Feb 28, 2024 | — |
| 144 | Notice of proposed sale | Feb 28, 2024 | — |
| 144 | Notice of proposed sale | Feb 28, 2024 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Feb 14, 2024 | — |
| 4 | Insider transaction | Jan 19, 2024 | Jan 17, 2024 |
| 4 | Insider transaction | Jan 19, 2024 | Jan 17, 2024 |
| 8-K |
Current report
Officer or director change
|
Dec 29, 2023 | Dec 29, 2023 |
| SC 13D/A | Amended ownership over 5% (active) | Dec 1, 2023 | — |
| 4 | Insider transaction | Dec 1, 2023 | Nov 29, 2023 |
| 4 | Insider transaction | Dec 1, 2023 | Nov 29, 2023 |
| 8-K |
Current report
Material agreement
|
Nov 24, 2023 | Nov 21, 2023 |
| 10-Q | Quarterly report | Nov 8, 2023 | Sep 30, 2023 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Nov 8, 2023 | Nov 8, 2023 |
| 8-K |
Current report
Other events
|
Oct 20, 2023 | Oct 17, 2023 |
| 10-Q | Quarterly report | Aug 9, 2023 | Jun 30, 2023 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Aug 9, 2023 | Aug 9, 2023 |
| 8-K |
Current report
Shareholder vote results
|
Jun 21, 2023 | Jun 16, 2023 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
May 9, 2023 | May 9, 2023 |
| 10-Q | Quarterly report | May 9, 2023 | Mar 31, 2023 |
| ARS | Annual report to shareholders | May 5, 2023 | Dec 31, 2022 |
| DEF 14A | Proxy statement | Apr 28, 2023 | Apr 27, 2023 |
| 10-K | Annual report | Mar 20, 2023 | Dec 31, 2022 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Mar 20, 2023 | Mar 20, 2023 |
| 8-K |
Current report
Officer or director change
|
Jan 18, 2023 | Jan 12, 2023 |
| SC 13G | Ownership over 5% (passive) | Nov 21, 2022 | — |
| 4 | Insider transaction | Nov 9, 2022 | Nov 8, 2022 |
| 4 | Insider transaction | Nov 9, 2022 | Nov 8, 2022 |
| 10-Q | Quarterly report | Nov 7, 2022 | Sep 30, 2022 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Nov 7, 2022 | Nov 7, 2022 |
| 4 | Insider transaction | Oct 24, 2022 | Oct 20, 2022 |
| 4 | Insider transaction | Sep 7, 2022 | Sep 2, 2022 |
| 4 | Insider transaction | Sep 7, 2022 | Sep 2, 2022 |
| 4 | Insider transaction | Aug 9, 2022 | Aug 6, 2022 |
| 10-Q | Quarterly report | Aug 8, 2022 | Jun 30, 2022 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Aug 8, 2022 | Aug 8, 2022 |
| 3 | Initial insider ownership | Jun 17, 2022 | Jun 8, 2022 |
| 8-K |
Current report
Shareholder vote results
|
Jun 14, 2022 | Jun 8, 2022 |
| DEFA14A | Additional proxy material | May 3, 2022 | — |
| 10-Q | Quarterly report | May 3, 2022 | Mar 31, 2022 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
May 3, 2022 | May 3, 2022 |
| DEF 14A | Proxy statement | Apr 27, 2022 | Jun 8, 2022 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Apr 26, 2022 | Apr 20, 2022 |
| 8-K |
Current report
Other events
|
Apr 25, 2022 | Apr 25, 2022 |
| SC 13D/A | Amended ownership over 5% (active) | Mar 22, 2022 | — |
| 8-K |
Current report
Other events
|
Mar 22, 2022 | Mar 22, 2022 |
| 4 | Insider transaction | Mar 21, 2022 | Mar 17, 2022 |
| 10-K | Annual report | Mar 10, 2022 | Dec 31, 2021 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Mar 10, 2022 | Mar 10, 2022 |
| 8-K |
Current report
Other events
|
Jan 24, 2022 | Jan 24, 2022 |
| SC 13G/A | Amended ownership over 5% (passive) | Jan 11, 2022 | — |
| 8-K |
Current report
Other events
|
Nov 22, 2021 | Nov 22, 2021 |
| 4 | Insider transaction | Nov 8, 2021 | Nov 4, 2021 |
| 4 | Insider transaction | Nov 8, 2021 | Nov 4, 2021 |
| 4 | Insider transaction | Nov 8, 2021 | Nov 4, 2021 |
| 4 | Insider transaction | Nov 8, 2021 | Nov 4, 2021 |
| 4 | Insider transaction | Nov 8, 2021 | Nov 4, 2021 |
| 4 | Insider transaction | Nov 2, 2021 | Oct 29, 2021 |
| 4 | Insider transaction | Nov 2, 2021 | Oct 29, 2021 |
| 10-Q | Quarterly report | Nov 1, 2021 | Sep 30, 2021 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Nov 1, 2021 | Nov 1, 2021 |
| 10-Q | Quarterly report | Jul 29, 2021 | Jun 30, 2021 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Jul 29, 2021 | Jul 29, 2021 |
| EFFECT | Filing | Jul 12, 2021 | — |
| CORRESP | Letter to the SEC | Jul 8, 2021 | — |
| UPLOAD | Letter from the SEC | Jul 7, 2021 | — |
| S-3 | Shelf registration | Jul 2, 2021 | — |
| 8-K |
Current report
Shareholder vote results
|
May 25, 2021 | May 19, 2021 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
May 3, 2021 | May 3, 2021 |
| 10-Q | Quarterly report | May 3, 2021 | Mar 31, 2021 |
| DEFA14A | Additional proxy material | Apr 9, 2021 | — |
| DEF 14A | Proxy statement | Apr 9, 2021 | May 19, 2021 |
| 10-K | Annual report | Mar 10, 2021 | Dec 31, 2020 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Mar 10, 2021 | Mar 10, 2021 |
| SC 13G | Ownership over 5% (passive) | Feb 16, 2021 | — |
| SC 13G | Ownership over 5% (passive) | Feb 16, 2021 | — |
| SC 13G | Ownership over 5% (passive) | Jan 25, 2021 | — |
| 4 | Insider transaction | Jan 19, 2021 | Jan 14, 2021 |
| 424B4 | Prospectus | Jan 15, 2021 | — |
| S-1MEF | Registration statement | Jan 15, 2021 | — |
| EFFECT | Filing | Jan 14, 2021 | — |
| CORRESP | Letter to the SEC | Jan 11, 2021 | — |
| FWP | Free writing prospectus | Jan 11, 2021 | — |
| CORRESP | Letter to the SEC | Jan 8, 2021 | — |
| S-1 | Registration statement | Jan 8, 2021 | — |
| 8-K |
Current report
Material agreement, Other events
|
Jan 6, 2021 | Dec 30, 2020 |
| UPLOAD | Letter from the SEC | Dec 21, 2020 | — |
Showing 200 filings, the most recent 200. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- LTRN (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- TX
- Headquarters
- Dallas, TX
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1763950
- Former names
- Lantern Pharma (until Jan 14, 2019)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.